A Closer Look at 5 Analyst Recommendations For Avidity Biosciences
Portfolio Pulse from Benzinga Insights
Avidity Biosciences (NASDAQ:RNA) received mixed analyst ratings, with a shift towards bullish sentiment in the last quarter. The average 12-month price target is now $35.2, down from $36.50. Analysts from Chardan Capital, Needham, and Wells Fargo provided updates, with one raising the price target from $23.00 to $33.00. The company's financials show a -20.8% revenue decline and a net margin of -2756.18%, indicating challenges despite a strong ROE of -11.87% and a low debt-to-equity ratio.
March 05, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Avidity Biosciences received mixed but mostly bullish analyst ratings, with a slight decrease in the average price target to $35.2. Financial challenges are evident with a significant revenue decline and a high net margin loss.
The mixed analyst ratings with a slight bullish tilt and a minor decrease in the average price target suggest a neutral short-term impact on RNA's stock price. The financial challenges highlighted, including a significant revenue decline, are concerning but may be somewhat mitigated by the company's strong ROE and low debt levels. The overall sentiment from analysts and the financial health of the company suggest a cautious outlook.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100